Koru Pharma’s premium hyaluronic acid fillers AVALON™ have recently been granted product approval by the Federal Service for Surveillance in Healthcare of Russian Federation. This significant milestone marks a pivotal moment for the company, particularly as all four types of the ‘HA Dermal Filler – AVALON™ PLUS’, which include Lidocaine, have received regulatory clearance. With this approval in place, Koru Pharma anticipates a notable uptick in sales momentum.
Expressing enthusiasm over the achievement, the CEO of Koru Pharma highlighted the seamless progression of their international expansion efforts. With the recent product approval in Russia, Koru Pharma is poised for further global market penetration, leveraging its outstanding products and cutting-edge technology.
“Our commitment to expanding our footprint globally remains unwavering,” stated the company’s CEO. “With our exceptional products and technology, we are dedicated to enhancing our presence and influence in the international market.” This latest approval underscores Koru Pharma’s commitment to delivering innovative solutions and advancing the field of aesthetic medicine on a global scale.
Original article published on NEWSPIM
